We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aclaris (ACRS) Common Warts Candidate Positive in Phase II
Read MoreHide Full Article
Aclaris Therapeutics, Inc. (ACRS - Free Report) announced positive results from a phase II study (WART-201) on A-101 Topical solution (A-101) for the treatment of common warts (verruca vulgaris).
The study evaluated the safety and dose-response of two concentrations of the A-101 Topical solution (40% and 45%), in comparison with placebo (vehicle).
Results from the study revealed that patients treated with the 45% formulation demonstrated a statistically significant change in Physician’s Wart Assessment (PWA) score, as well as complete clearance of the target wart after one week of treatment, compared to placebo. Moreover, the candidate was well tolerated, with local skin reactions being mostly mild in severity and similar to the placebo arm.
As per the company’s press release, about 1.9 million people are diagnosed with common warts on an annual basis.
Apart from common warts, Aclaris is also evaluating A-101 in two phase III pivotal studies and a phase III open-label safety study for the treatment of seborrheic keratosis. Aclaris expects to report initial results in the fourth quarter of 2016. Thereafter, the company plans to submit a New Drug Application in the U.S. in the first quarter of 2017 and a Marketing Authorization Application in the EU in mid 2017, assuming positive results.
We expect investors to remain focus on further pipeline updates from the company, going forward.
Aclaris currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Geron Corporation (GERN - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Aclaris (ACRS) Common Warts Candidate Positive in Phase II
Aclaris Therapeutics, Inc. (ACRS - Free Report) announced positive results from a phase II study (WART-201) on A-101 Topical solution (A-101) for the treatment of common warts (verruca vulgaris).
The study evaluated the safety and dose-response of two concentrations of the A-101 Topical solution (40% and 45%), in comparison with placebo (vehicle).
Results from the study revealed that patients treated with the 45% formulation demonstrated a statistically significant change in Physician’s Wart Assessment (PWA) score, as well as complete clearance of the target wart after one week of treatment, compared to placebo. Moreover, the candidate was well tolerated, with local skin reactions being mostly mild in severity and similar to the placebo arm.
As per the company’s press release, about 1.9 million people are diagnosed with common warts on an annual basis.
Apart from common warts, Aclaris is also evaluating A-101 in two phase III pivotal studies and a phase III open-label safety study for the treatment of seborrheic keratosis. Aclaris expects to report initial results in the fourth quarter of 2016. Thereafter, the company plans to submit a New Drug Application in the U.S. in the first quarter of 2017 and a Marketing Authorization Application in the EU in mid 2017, assuming positive results.
ACLARIS THERAPT Price
ACLARIS THERAPT Price | ACLARIS THERAPT Quote
We expect investors to remain focus on further pipeline updates from the company, going forward.
Aclaris currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Geron Corporation (GERN - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>